2014
DOI: 10.1074/jbc.m114.609453
|View full text |Cite
|
Sign up to set email alerts
|

UL52 Primase Interactions in the Herpes Simplex Virus 1 Helicase-Primase Are Affected by Antiviral Compounds and Mutations Causing Drug Resistance

Abstract: Background: Herpes simplex virus DNA synthesis requires seven interacting virus proteins.Results: Mapping revealed an N-terminal domain of UL52 primase interacting with UL5 helicase; a UL52 middle domain binds UL8 and the UL29 single strand DNA-binding protein.Conclusion: Protein-protein interactions in the helicase-primase were affected by an antiviral compound and resistance mutations.Significance: This work provides understanding of antiviral inhibition of replisome function.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0
1

Year Published

2015
2015
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(16 citation statements)
references
References 31 publications
0
15
0
1
Order By: Relevance
“…Thus, the putative antigenic determinants of glycoprotein B and major capsid protein might be potential targets for epitope-based vaccine development for protective immune response against infections caused by HHVs. Although no antigenic determinant is located in helicase enzyme of HHVs, the complex of this enzyme with primase is suggested to be an efficient drug target against the infections caused by HSV-1 [ 27 ], HSV-2 [ 28 ], and HHV-3 [ 29 ]. Thus, helicase and putative antigenic determinants of glycoprotein B and major capsid protein of HHVs may become effective targets for drug and vaccine development; experimental investigations are required to develop therapeutics and drugs using these targets.…”
Section: Resultsmentioning
confidence: 99%
“…Thus, the putative antigenic determinants of glycoprotein B and major capsid protein might be potential targets for epitope-based vaccine development for protective immune response against infections caused by HHVs. Although no antigenic determinant is located in helicase enzyme of HHVs, the complex of this enzyme with primase is suggested to be an efficient drug target against the infections caused by HSV-1 [ 27 ], HSV-2 [ 28 ], and HHV-3 [ 29 ]. Thus, helicase and putative antigenic determinants of glycoprotein B and major capsid protein of HHVs may become effective targets for drug and vaccine development; experimental investigations are required to develop therapeutics and drugs using these targets.…”
Section: Resultsmentioning
confidence: 99%
“…However, unlike HSVprotein targeting helicase-primase inhibitors, peg-ArgI modulation of host arginine-associated metabolic pathways minimizes the likelihood that viruses could evolve resistance. This would contrast virus-targeted nucleoside analogs and helicase-primase inhibitors where mutations that confer resistance are easily identified (Biswas et al, 2007; Coen and Schaffer, 1980; Fleming and Coen, 1984; Muylaert et al, 2014; Pelosi et al, 1998). …”
Section: Discussionmentioning
confidence: 99%
“…ICP8 presumably stimulates synthesis on the leading strand by preventing reannealing of ssDNA unwound by UL5/UL8/UL52. In addition, the direct interaction between ICP8, UL8, and UL52 has been reported recently (19). The collaboration of ICP8 with the subunits of the helicase/primase might be required for the coupled synthesis.…”
Section: Discussionmentioning
confidence: 94%